Partnering with Patients to Improve Therapeutic Outcomes: Incretin-Based Therapy for Type 2 Diabetes

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

(2009) Nancy M. Yoon et al.   CLINICAL THERAPEUTICS

Treating diabetes and prediabetes by focusing on obesity management

(2009) Lalita Khaodhiar et al.   Current Diabetes Reports

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

A Comparison of Insulin Injection Needles on Patients' Perceptions of Pain, Handling, and Acceptability: A Randomized, Open-Label, Crossover Study in Subjects with Diabetes

(2009) Maureen McKay et al.   Diabetes Technology & Therapeutics

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Long-Term Weight Loss From Lifestyle Intervention Benefits Blood Pressure?

(2009) Lorna Aucott et al.   HYPERTENSION

A Moderate-Protein Diet Produces Sustained Weight Loss and Long-Term Changes in Body Composition and Blood Lipids in Obese Adults

(2009) Donald K. Layman et al.   JOURNAL OF NUTRITION

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

(2009) Jay S. Skyler et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization

(2008) E. M. Davis et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Use of Thiazolidinediones and Fracture Risk

(2008) Christian Meier et al.   ARCHIVES OF INTERNAL MEDICINE

The UPS in diabetes and obesity

(2008) Simon S Wing   BMC BIOCHEMISTRY

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

The why WAIT program: Improving clinical outcomes through weight management in type 2 diabetes

(2008) Osama Hamdy et al.   Current Diabetes Reports

Prefilled insulin device with reduced injection force: patient perception and accuracy

(2008) A. Pfützner et al.   CURRENT MEDICAL RESEARCH AND OPINION

Exendin-4 Protects  -Cells From Interleukin-1 -Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase Pathway

(2008) M. Ferdaoussi et al.   DIABETES

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

Insulin Resistance: A Proinflammatory State Mediated by Lipid-Induced Signaling Dysfunction and Involved in Atherosclerotic Plaque Instability

(2008) Fabrizio Montecucco et al.   MEDIATORS OF INFLAMMATION

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exendin-4 Improves the Oral Glucose Tolerance in Diabetic Rats: Pancreas Regeneration, Better Function of Pancreatic Islets, or Impaired Glucose Uptake?

(2008) A. Strauss et al.   TRANSPLANTATION PROCEEDINGS

Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus

(2007) Michael E. Minshall et al.   VALUE IN HEALTH